Multiple Myeloma

>

Latest News

Ide-Cel Receives Favorable ODAC Vote for R/R Multiple Myeloma
Ide-Cel Receives Favorable ODAC Vote for R/R Multiple Myeloma

March 15th 2024

The ODAC meeting concluded that ide-cel showed a favorable risk/benefit profile for patients with pretreated relapsed/refractory multiple myeloma.

ODAC voted on the risk/benefit ratio of cilta-cel vs standard of care for patients with lenalidomide-refractory multiple myeloma.
ODAC Casts 11 to 0 Vote in Favor of Cilta-Cel in R/R Multiple Myeloma

March 15th 2024

ASH 2023: The Most Relevant Multiple Myeloma Data Presented
ASH 2023: The Most Relevant Multiple Myeloma Data Presented

March 13th 2024

Patient-reported outcomes support the clinical benefits of ide-cel among patients with relapsed/refractory multiple myeloma.
Ide-cel Improves HRQOL Vs Standard Treatment in R/R Multiple Myeloma

March 12th 2024

The DREAMM-8 trial assessing belantamab mafodotin plus pomalidomide/dexamethasone met the primary end point for those with relapsed/refractory multiple myeloma.
Belantamab Mafodotin Combo Improves PFS Vs SOC in R/R Multiple Myeloma

March 7th 2024

Video Series
Video Interviews
Podcasts
Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.
Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.
Krina Patel, MD, MSc, discusses research and initiatives that may help to mitigate disparities in patients with multiple myeloma including factors such as gender, race, and ethnicity.
Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma.
Latest CME Events & Activities

Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes

View More

From Trials to the Real World: Assessing the Role of Allogeneic Transplant and JAK Inhibitors as Treatment Paradigms Evolve in Myelofibrosis

View More

Expert Illustrations and Commentaries™: Evaluating the Potential for Novel Mechanistic Approaches to Overcome Clinical Gaps in the Care of Patients with LR-MDS

View More

Medical Crossfire®: Expert Perspectives in Geographic Atrophy – How Can We Prepare for a New Era of Treatment?

View More

Clinical Vignettes™: Integrating Novel CAR T-Cell Therapies Across Lymphoid Malignancies with an Eye Toward the Future of Care

View More

Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma

View More

Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment

View More

B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence

View More

Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease

View More

Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat

View More

Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

More News